News | August 08, 2007

CFCF Optimistic about Co-Hosting 2007 Carcinoid Research Summit

August 9, 2007 – The Caring for Carcinoid Foundation (CFCF) hopes to co-host the 2007 Carcinoid Research Summit with the National Cancer Institute (NCI).
Through their "Move Toward a Cure" Campaign, CFCF led the carcinoid/NET community to voice support for Congressional legislation. The campaign proved highly successful, resulting in hundreds of letters to 80 U.S. Senators and 83 U.S. Representatives.
The "Move Toward a Cure" campaign also spurred several carcinoid patient support groups to take action and conduct follow-up efforts. CFCF’s current objective is to co-host the "2007 Carcinoid Research Summit" with the National Cancer Institute (NCI):
- To create a common vision for carcinoid research
- To assemble top carcinoid researchers to discuss their findings
- To identify new opportunities for research collaboration
- To raise public awareness of carcinoid research
- To potentially increase NCI funding of carcinoid research

If CFCF’s fundraising target of $50,000 is reached, they will move ahead with co-hosting the Carcinoid Research Summit.
For more information:

Related Content

MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
Overlay Init